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Protein-disulfide isomerase (PDI) has been proposed to
exhibit an “unfoldase” activity against the catalytic A1 subunit
of cholera toxin (CT). Unfolding of the CTA1 subunit is thought
to displace it from the CT holotoxin and to prepare it for trans-
location to the cytosol. To date, the unfoldase activity of PDI has
not been demonstrated for any substrate other than CTA1. An
alternative explanation for theputative unfoldase activity of PDI
has been suggested by recent structural studies demonstrating
that CTA1 will unfold spontaneously upon its separation from
the holotoxin at physiological temperature. Thus, PDImay sim-
ply dislodgeCTA1 from theCTholotoxinwithout unfolding the
CTA1 subunit. To evaluate the role of PDI in CT disassembly
and CTA1 unfolding, we utilized a real-time assay to monitor
the PDI-mediated separation of CTA1 from the CT holotoxin
and directly examined the impact of PDI binding on CTA1
structure by isotope-edited Fourier transform infrared spec-
troscopy. Our collective data demonstrate that PDI is required
for disassembly of the CT holotoxin but does not unfold the
CTA1 subunit, thus uncovering a newmechanism forCTA1dis-
sociation from its holotoxin.
Cholera toxin (CT)2 is an AB5 protein toxin that consists of a
catalytic A moiety and a cell-binding B moiety (1, 2). The B
subunit is pentameric ring-like structure that adheres to GM1
gangliosides on the plasma membrane of a target cell. The A
subunit is initially synthesized as a 26 kDa protein that under-
goes proteolytic nicking to generate a disulfide-linked A1/A2
heterodimer. The 21 kDaCTA1 polypeptide is anADP-ribosyl-
transferase thatmodifies and activatesGs in the host cell cyto-
sol. CTA1 can be divided into three subdomains: the A11 sub-
domain contains the catalytic core of the toxin; the A12
subdomain is a short extended linker that connects the A11 and
A13 subdomains; and theA13 subdomain is a globular structure
with many hydrophobic residues as well as a cysteine residue
involved with the single disulfide bridge between CTA1 and
CTA2 (3). The 5 kDa CTA2 polypeptide maintains numerous
non-covalent interactions with the central pore of the B penta-
mer and thereby anchors CTA1 to CTB5. A ribbon diagram of
the CT holotoxin which highlights the subdomain structure of
CTA1 is provided in supplemental Fig. S1.
To reach its cytosolic Gs target, CT moves from the cell
surface to the endoplasmic reticulum (ER) by retrograde vesic-
ular traffic (4). A C-terminal KDEL sequence in the CTA2 sub-
unit is thought to target and/or retain CT in the ER (4, 5). Con-
ditions in the ER lead to reductive cleavage of the CTA1/CTA2
disulfide bond and chaperone-assisted dissociation of CTA1
fromCTA2/CTB5 (6–9). Unfolding of the free A1 subunit then
activates the quality control system of ER-associated degrada-
tion (ERAD), thereby promoting CTA1 translocation to the
cytosol (10, 11). Most exported ERAD substrates are degraded
by the ubiquitin-proteasome system, but it was hypothesized
that CTA1 and the A chains of other ER-translocating toxins
avoid this fate because they lack substantial numbers of lysine
residues for ubiquitin conjugation (12). Subsequent experi-
mental studies verified the paucity of lysine residues protects
CTA1 and other toxin A chains from ubiquitin-dependent pro-
teasomal degradation (13–15). The translocated pool of CTA1
instead interacts with ADP-ribosylation factors and possibly
other host factors to regain an active, folded conformation in
the cytoplasm (16–18).
The reduced form of protein-disulfide isomerase (PDI), an
ER-localized oxidoreductase andmolecular chaperone (19, 20),
was originally proposed to unfold the holotoxin-associated
CTA1 subunit and to thereby promote the separation of CTA1
from CTA2/CTB5 (9). It was further posited that unfolding of
the CTA1 polypeptide was directly coupled with toxin delivery
to the Derlin-1 pore (21, 22). Release of CTA1 from PDI in
preparation for translocation through the Derlin-1 pore was
thought to involve the oxidation of PDI by Ero1p (23). Thus,
PDI is viewed as a redox-dependent chaperone that binds to
holotoxin-associated CTA1 in a reduced state, actively unfolds
the toxin, and then releases the dissociated CTA1 subunit upon
its oxidation by Ero1p.
Many aspects of PDI-CTA1 interactions remain controver-
sial. Lumb and Bulleid demonstrated that PDI does not act in a
redox-dependent fashion when assisting the folding of other
polypeptide chains (24). Recent experiments using zebrafish
and mammalian cells have questioned the role of Derlin-1 in
CTA1 translocation (25). Our structural studies have indicated
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that CTA1 will unfold spontaneously after dissociation from
the holotoxin at physiological temperature (17, 26, 27). It is
therefore possible that, in terms of cholera intoxication, the
primary function of PDI is to simply dislodge CTA1 from
CTA2/CTB5. The dissociated CTA1 polypeptide would then
spontaneously unfold and consequently trigger the ERAD
translocation mechanism.
In this work we evaluated the role of PDI in disassembly of
the CT holotoxin and unfolding of the CTA1 subunit. The pre-
vailing model of PDI-toxin interactions is largely based upon
the results of a protease sensitivity assay which demonstrated
that CTA1 shifts from a protease-resistant conformation to a
protease-sensitive conformation in the presence of reduced
PDI (9, 13, 23, 28, 29). As folded proteins are generally more
resistant to proteolysis than unfolded variants of the same pro-
tein, this shift was interpreted to represent the PDI-induced
unfolding ofCTA1 and thePDI-induceddisplacement ofCTA1
from CTA2/CTB5. Yet this assay, which was typically per-
formed at 30 °C, only provides an indirect measure of protein
folding. Here, we developed a surface plasmon resonance (SPR)
assay to directly monitor in real time the disassembly of the CT
holotoxin. Biophysical methods were used to directly examine
the conformation of CTA1 in the presence or absence of PDI.
Cell-based assays further probed the role of PDI in CT intoxi-
cation and CTA1 translocation. Our collective data indicate
that PDI does not unfold the CTA1 polypeptide and that PDI
can displace CTA1 from CTA2/CTB5 in a process which does
not involve substantial alterations to the structure of CTA1. In
further contrast with the current model of PDI-toxin interac-
tions where PDI acts as an unfoldase, we found that the PDI-
induced shift of CTA1 to a protease-sensitive conformation
does not correlate to the disassembly of the CT holotoxin.
Moreover, the release of PDI from CTA1 does not require
Ero1p but instead results from the spontaneous unfolding of
CTA1 which occurs after its dissociation from the holotoxin.
The unstable nature of the isolated CTA1 polypeptide at phys-
iological temperature thus plays a central role in toxin translo-
cation and leads to a new model of CT disassembly in the ER.
EXPERIMENTAL PROCEDURES
Materials—His-tagged CTA1, CTA11–168, and CTA11–133
constructs were purified as previously described (26). CT and
the CTA1/CTA2 heterodimer were purchased from List Bio-
logicals (Campbell, CA), while PDI, chemicals, and other
reagents were purchased from Sigma-Aldrich. Anti-CTA and
anti-CTB antibodieswere purchased fromSigma-Aldrich; anti-
PDI and anti-KDEL antibodies were purchased from Enzo Life
Sciences (PlymouthMeeting, PA); and the anti-CTAmonoclo-
nal antibody 35C2 (30) was kindly provided by Dr. Randall K.
Holmes (University of Colorado Denver School of Medicine).
SPR—Experiments were performed with a Reichert (Depew,
NY) SR7000 SPR Refractometer as previously described (17).
Antibodies were perfused over the plate at the following dilu-
tions in phosphate-buffered saline containing 0.05% Tween 20:
anti-PDI antibody, 1:10,000; anti-CTB antibody, 1:15,000; anti-
CTA monoclonal antibody, 1:500; anti-CTA polyclonal anti-
body, 1:5,000; and anti-KDEL antibody, 1:10,000. The flow rate
for all steps was 41 l/min.
13C Labeling and Purification of CTA1-His6—Escherichia
coli strain BL21 pLysS was transformed with pT7CTA1h6, an
inducible CTA1-His6 expression plasmid (31). 13C-labeled
toxin was generated by culturing the strain at 37 °C inM9min-
imal media supplemented with uniformly 13C-labeled 13C6-D-
glucose (Cambridge Isotope, Andover, MA) as the sole meta-
bolic carbon source. The culture was shifted to 22 °C when it
reached an A600 of 0.6, and protein expression was induced
overnight by the addition of 1mM IPTG. The expressed protein
was then purified in 8Murea buffer as described previously (26).
The purity of the protein sample was assessed by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
withCoomassie staining. In order to facilitate protein refolding,
slide-a-lyzer 3500MWCOcassettes (Pierce) were used for dial-
ysis as previously described (27). After dialysis, CTA1-His6 was
lyophilized for FTIR experiments. Control experiments using
circular dichroism (CD) confirmed that lyophilization did not
alter the structure of CTA1.
Determination of Protein Secondary Structure by Fourier
Transform Infrared (FTIR) Spectroscopy—Protein samples for
FTIRmeasurements were prepared in a D2O-based buffer con-
taining 10 mM sodium borate pH* 6.6 that corresponds to pH
7.0. The samples contained either unlabeled PDI, uniformly
13C-labeled CTA1, or both PDI and 13C-labeled CTA1 at a 1:1
molar ratio. FTIR spectra were measured on a Jasco 4200 FTIR
spectrometer at 0.964 cm1 spectral resolution and a set reso-
lution of 1 cm1. The absorbance spectra were calculated using
the respective buffers as reference and corrected by subtraction
of H2O vapor contribution, smoothing, and baseline correction
in the amide I region. Curve fitting was conducted using the
component frequencies from the second derivative spectra, as
described in (32, 33) and elaborated upon in the supplemental
data. No appreciable signals from the second derivative spectra
were detected in the region above 1700 cm1.
Toxicity Assay—Cells were seeded into 24-well plates and
grown overnight to 80% confluency. Themediumwas removed
and replaced with serum-free medium containing various con-
centrations of CT. After 2 h, the cells were processed for deter-
mination of cAMP levels as described inRef. 34. The basal levels
of cAMP determined from unintoxicated cells were back-
ground-subtracted from the values obtained for toxin-treated
cells; the maximal response from the parental control cells was
arbitrarily set to 100%; and all other results were expressed as
ratios of that 100% value. All conditions were performed in
triplicate.
CTA1 Transfection Assays—Cells seeded to 80% confluency
in 6-well plates were transfected with pcDNA3.1/ssCTA1 (35)
using Lipofectamine (Invitrogen) according as permanufactur-
er’s instructions. For the translocation assay, cells were incu-
bated at 24 h post-transfection in methionine-free medium for
1 h before [35S]methionine was added for another hour. Digi-
tonin was then used to generate separate membrane and cyto-
solic fractions as previously described (34). Both cellular frac-
tions were immunoprecipitated with an anti-CTA antibody.
SDS-PAGEwith PhosphorImager analysis was used to visualize
and quantify the immunoisolatedmaterial. The extent of CTA1
translocation for each cell linewas calculatedwith the following
Role of PDI in Cholera Intoxication
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equation: % cytosolic CTA1  CTA1 supernatant signal/
[CTA1 supernatant signal CTA1 pellet signal].
For the toxicity assay, cells were exposed to ice-cold acidic
ethanol at 3 h post-transfection and were processed for deter-
mination of cAMP levels as described in (34). An additional set
of transfected cells were chased overnight to determine the rel-
ative levels of CTA1 expression via metabolic labeling and
immunoprecipitation. Values obtained from the cAMP assay
were standardized to CTA1 expression levels before expressing
the data as percentages of the signal obtained from the parental
control cells.
RESULTS
PDI-mediated Disassembly of the CT Holotoxin—SPR was
used to examine the interaction between CT and PDI (Fig. 1).
CT was appended to a GM1-coated sensor slide, and anti-CTA
or anti-CTB antibodies were perfused over the slide for control
measurements (Fig. 1A). Both antibodies generated an increase
in the refractive index of the sensor slide, thus indicating direct
antibody binding to the CT holotoxin. The anti-CTB antibody
produced a stronger signal than the anti-CTA antibody
because, given the AB5 structure of the holotoxin, there was
5-fold more CTB than CTA on the sensor slide. Differences in
antibody affinity could also account for some of the differences
in anti-CTB versus anti-CTA signal strength. The anti-KDEL
antibody did not produce a positive signal (Fig. 1A), possibly
because the presence of the CTA1 subunit blocked antibody
access to the KDEL tag at the C terminus of CTA2 (supplemen-
tal Fig. S1). PDI and oxidized PDI did not bind to the CT holo-
toxin (Fig. 1A), but an interaction between reduced PDI andCT
was detected (Fig. 1B). These observationswere consistent with
a published report on the redox-dependent interplay between
PDI and CT (9).
Previous work has shown that reduced PDI can remove
CTA1 from the CT holotoxin (9). This event was documented
by our SPR system as well (Fig. 1B). After PDI bound to the CT
holotoxin, a time-dependent loss of signal was observed. This
indicated that PDI was released from the CT sensor slide after
its initial binding. If only PDI was lost from the sensor, then the
signal strength would revert to the baseline value which was
derived from the mass of the bound holotoxin. However, the
signal actually dropped to a negative value. This indicated that a
portion of the holotoxin had also been released from the sensor
slide. To confirm that reduced PDI had displaced CTA1 from
the holotoxin, anti-CTA antibodies were perfused over the CT
sensor slide. In contrast to our control experiment with the
intact CT holotoxin (Fig. 1A), the anti-CTA antibody did not
generate an increase in the refractive index of the PDI-treated
holotoxin (Fig. 1B). CTA1 was therefore absent from the PDI-
treated CT sensor slide. Perfusion of an anti-PDI antibody over
the sensor slide also demonstrated that PDI was absent from
the plate (Fig. 1B). Previous reports have demonstrated that
reduction of the CTA1/CTA2 disulfide bond is not sufficient to
remove CTA1 from the holotoxin (9, 36), which was also doc-
umented in our SPR system: the CT holotoxin remained intact
when exposed to a reducing perfusion buffer containing 1 mM
GSH (data not shown). Thus, reduced PDI displaced CTA1
from the CT holotoxin. This effect was documented with a
range of PDI concentrations, and the amount of reduced PDI in
the perfusion buffer was directly related to the kinetics of holo-
toxin disassembly (supplemental Fig. S2).
To determine the fate of the CTA2 polypeptide after holo-
toxin disassembly, we perfused an anti-KDEL antibody over the
PDI-treated holotoxin (Fig. 1B). The anti-KDEL antibody did
not generate an increase in the refractive index when applied to
the intact CT holotoxin (Fig. 1A), but a positive signal was
obtained when the antibody was applied to the PDI-treated
holotoxin (Fig. 1B). Removal of the CTA1 subunit thus allowed
the anti-KDEL antibody to reach the KDEL tag on the CTA2
FIGURE 1.Dissociation of the CT holotoxin by reduced PDI. A, following ligands were perfused over a CT-coated SPR sensor slide at 37 °C: PDI, oxidized PDI
(PDI 1mMGSSG), an anti-CTA antibody, an anti-CTB antibody, and an anti-KDEL antibody. B, after taking a baselinemeasurement corresponding to themass
of the sensor-bound holotoxin, reduced PDI (PDI  1 mM GSH) was perfused over the CT-coated sensor slide at 37 °C. PDI was removed 400 s into the
experiment and replaced with sequential additions of anti-PDI, anti-CTA, and anti-KDEL antibodies as indicated by the arrowheads.
Role of PDI in Cholera Intoxication
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subunit that remained associated with the sensor-bound CTB
pentamer. Reduced PDI thus displaced CTA1 from the CT
holotoxin but did not separate CTA2 from CTB5.
Structure-dependent Interactions between PDI and CTA1—
Reduced PDI did not bind to CTA2/CTB5 (supplemental Fig. S3),
but it did interact with the isolated CTA1 subunit (Fig. 2). As seen
with the CT holotoxin, only reduced PDI could interact with
CTA1:neitherPDInoroxidizedPDI increased the refractive index
whenperfusedoveraCTA1sensor slide (datanot shown).Binding
of reduced PDI to CTA1 was temperature-dependent. A strong
interaction was detected at 10 °C, a weaker interaction was
detected at 25 °C, and little to no interactions were detected at
33 °C or the physiological temperature of 37 °C (Fig. 2A). The iso-
latedCTA1 subunit is a thermally unstable proteinwith a partially
perturbed secondary structure and a disordered tertiary structure
at 37 °C (17). It thus appeared that PDI can interact with the
folded conformations of CTA1 present at low temperatures
but not with the unfolded CTA1 conformations present at
physiological or near-physiological temperatures. Thermal
instability in the CTA1 polypeptide is only apparent after
dissociation from the holotoxin (17, 37, 38), which explains
why reduced PDI could interact with CTA1 when it was
present in the CT holotoxin at 37 °C (Fig. 1B).
The C-terminal A13 subdomain of CTA1 has been proposed
to act as the trigger for ERAD-mediated translocation and to
serve as the site for PDI binding (12, 39).However, a CTA1
variant lacking most of the A13 subdomain (CTA11–169) can still
move from the ER to the cytosol (31).We found that a CTA11–168
variant could also interact with reduced PDI (Fig. 2B). As with the
full-length CTA1, PDI binding to CTA11–168 was temperature-
dependent: a strong interaction was detected at 10 °C, a weaker
interaction was detected at 25 °C, and no interactions were
detected at 33 °C or 37 °C (Fig. 2B). A similar pattern of tem-
perature-dependent binding was recorded for the interaction
between PDI and CTA11–133, a CTA1 variant lacking both the
A12 and A13 subdomains (Fig. 2C). Increasing the temperature
from 10 to 37 °C results in a progressive loss of structure for
CTA1, CTA11–168, and CTA11–133 (27). PDI thus appeared to
recognize a folded region in the A11 subdomain of CTA1.
The CTA11–133 construct is less stable than either CTA1 or
CTA11–168 (27), which explains the weaker binding of PDI to
CTA11–133 at 25 °C in comparison to CTA1 and CTA11–168.
These experiments highlighted a unique aspect of PDI-CTA1
interactions, as PDI usually binds to unfolded but not folded
protein conformations (19, 20).
When exposed to mildly acidic pH, the isolated CTA1 sub-
unit retains a substantial amount of its native structure at phys-
iological temperature (27). Consistentwith this observation, we
found that an acidic perfusion buffer allowed reduced PDI to
effectively bind free CTA1 at 37 °C (Fig. 3A). This again sug-
gested that PDI recognizes a structure in the folded conforma-
tion of CTA1. It also demonstrated, along with the holotoxin
study of Fig. 1B, that reduced PDI was functional in our SPR
system at 37 °C. Interestingly, PDI was rapidly displaced from
CTA1 when the acidic buffer was replaced with neutral buffer
(Fig. 3B). The high affinity interaction between CTA1 and PDI
that occurred at pH 6.5 was completely lost, as reflected by the
return of the signal to baseline value, when the 37 °C buffer was
switched to neutral pH. The disruption of PDI binding
occurred despite the continued presence of PDI in the pH 7.0
perfusion buffer. Furthermore, the loss of PDI interaction was
not simply time-dependent: when the perfusion buffer was
maintained at pH 6.5, PDI remained stably associated with
CTA1 (Fig. 3A). CTA1would shift from a folded to an unfolded
conformation when the buffer was switched from pH 6.5 to pH
7.0. It therefore appeared that the thermal unfolding of CTA1
results in displacement of bound PDI.
To ensure that our pH data resulted from structural altera-
tions to CTA1, we repeated the PDI/CTA1 binding assay with
another condition that stabilizes the structure of CTA1: 10%
glycerol. Like acidic pH, treatment with 10% glycerol increases
the thermal stability of CTA1 and allows the toxin to maintain
a substantial amount of its native structure at 37 °C (26). Glyc-
erol treatment also allowed reduced PDI to effectively bind
CTA1 at 37 °C (Fig. 3C). This interaction was lost when glyc-
erol, but not PDI, was removed from the perfusion buffer (Fig.
3D). In contrast, PDI remained stably associated with CTA1
when 10%glycerol was kept in the perfusion buffer for the dura-
tion of the experiment (Fig. 3C). CTA1 would shift from a
folded to an unfolded conformation when glycerol was
removed from the 37 °C perfusion buffer. Thus, two indepen-
dent experimental conditions both indicated that toxin unfold-
ing will displace PDI from its CTA1 binding partner.
FIGURE 2.Conformation-dependent interactions betweenPDI andCTA1. Reduced PDI (PDI 1mMGSH)was perfused at the indicated temperatures over
SPR sensor slides coated with (A) CTA1, (B) CTA11–168, or (C) CTA11–133. PDI was removed from the perfusion buffer 150 s into the experiment.
Role of PDI in Cholera Intoxication
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PDI-mediated Disassembly of the CT Holotoxin Does Not
Require CTA1 Unfolding—PDI is thought to remove reduced
CTA1 fromCTA2/CTB5 by unfolding the holotoxin-associated
A1 subunit (9). According to this model, the resulting confor-
mational change in CTA1would disrupt its non-covalent inter-
actions with CTA2/CTB5 and thereby promote its dissociation
from the holotoxin. To determine if PDI could remove CTA1
fromCTA2/CTB5 without unfolding CTA1, we added reduced
PDI to a CT-coated sensor slide at pH 6.5 (Fig. 4A). The stable
interaction between PDI and CTA1 at 37 °C and pH 6.5 (Fig.
3A) indicated that PDI does not unfold CTA1 under these con-
ditions - otherwise, as shown in Fig. 4B, CTA1 unfolding would
displace the bound PDI. At both pH 7.0 (Fig. 1B) and pH 6.5
(Fig. 4A), reduced PDI displaced CTA1 from the CT holotoxin.
Likewise, reduced PDI could displace CTA1 from the CT holo-
toxin in the presence of 10% glycerol (26). It therefore appeared
that PDI can dislodgeCTA1 fromCTA2/CTB5without unfold-
ing the A1 subunit. To further examine this possibility, we
added PDI to the CT holotoxin at 10 °C or 4 °C. PDI does not
induce CTA1 to assume a protease-sensitive conformation at
4 °C, and this has been interpreted to mean that PDI cannot
unfold CTA1 at low temperatures (29). However, PDI could
still promote the dissociation of CTA1 from CTA2/CTB5 at
either 10 °C (Fig. 4B) or 4 °C (supplemental Fig. S4). This again
demonstrated that CTA1 unfolding was not required for its
dissociation from the CT holotoxin.
Heating the reduced CT holotoxin to 65 °C, a temperature
that results in irreversible denaturation of the holotoxin-asso-
ciated CTA1 subunit (37), did not result in the displacement of
CTA1 from CTA2/CTB5 (supplemental Fig. S5). It therefore
appeared that unfolding alone is insufficient to displace CTA1
from CTA2/CTB5. Collectively, these results suggested that
PDI removes CTA1 from CTA2/CTB5 by a mechanism that
does not involve unfolding of the holotoxin-associated CTA1
subunit.
To determine the fate of PDI after it facilitates the separation
of CTA1 from CTA2/CTB5, we repeated the disassembly assay
with a holotoxin that was appended to the SPR sensor slidewith
a rabbit anti-CTA antibody. CTA2, CTB5, and PDI were absent
from the sensor slide after PDI-mediated disassembly of the
holotoxin at 37 °C (Fig. 5). Use of an anti-CTA monoclonal
antibody confirmed that CTA1 was still on the plate. This
experiment demonstrated that PDI does not remain associated
with CTA1 after holotoxin disassembly.
PDI Does Not Unfold the CTA1 Polypeptide—To directly
examine the effect of PDI binding on the conformational state
FIGURE 3. CTA1 unfolding displaces toxin-bound PDI. A and B, reduced PDI (PDI 1 mM GSH) was perfused over a CTA1-coated sensor slide at 37 °C in pH
6.5 buffer. After 250 s, the pH of the perfusion buffer was either (A) maintained at pH 6.5 or (B) shifted to pH 7.0. PDI was present in the perfusion buffer
throughout the experiment. C andD, reduced PDI (PDI 1mM GSH) was perfused over a CTA1-coated sensor slide at 37 °C in buffer containing 10% glycerol.
After 250 s, glycerol was either (C) maintained or (D) removed from the perfusion buffer. PDI was present in the perfusion buffer throughout the experiment.
Role of PDI in Cholera Intoxication
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of CTA1, we performed structural studies using isotope-edited
FTIR spectroscopy. This method allows the conformation of a
13C-labeled protein to bemonitored in the presence of a second
unlabeled protein. 13C labeling does not alter the conformation
of a protein.However, the heavier nuclearmass of the stable 13C
isotope generates a spectral downshift which allows the FTIR
spectrum of a 13C-labeled protein to be resolved from the spec-
trum of an unlabeled protein (32, 40). The FTIR spectra of 13C-
labeled CTA1 accordingly exhibited a 50 cm1 shift in compar-
ison to the spectra of unlabeled CTA1 (supplemental Fig. S6A).
As expected, no structural differences between labeled and
unlabeled CTA1 were detected by CD over a range of temper-
atures (supplemental Fig. S6, B and C).
The down-shifted FTIR spectra of 13C-labeled CTA1 could
be readily distinguished from the spectra of PDI (Fig. 6), allow-
ing us to directly examine the impact of PDI onCTA1 structure.
Analysis of the 10 °C FTIR spectrum from CTA1 alone indi-
cated that the folded toxin contains 37% -helical and 45%
-sheet content (Fig. 7, A and B, Table 1). This result was con-
sistent with the 36% -helix/51% -sheet content predicted
from the crystal structure of the folded, holotoxin-associated
CTA1 subunit (41). The -helical, -sheet, and irregular (often
referred to as “random”) structures of CTA1 were unaltered in
the presence of PDI (Fig. 7, C and D, Table 1). Thus, the inter-
action between PDI and CTA1 at 10 °C which displaces CTA1
from the CT holotoxin (Fig. 4B) did not result in any significant
disordering of the CTA1 polypeptide. In contrast, because of its
intrinsic thermal instability, heating CTA1 alone at neutral pH
(supplemental Fig. S7) shifted the percentage of its irregular
structure from 8% at 10 °C to 53% at 37 °C (Table 1). The gain in
irregular structure was accompanied by a loss of both -helical
and-sheet structure. These observations were consistent with
previous CDmeasurements that documented the partially dis-
FIGURE4.CTdisassemblyunder conditions thatprevent theunfoldingofCTA1.After appendingCT toaGM1-coated sensor slide, abaselinemeasurement
corresponding to the mass of the bound holotoxin was recorded. Reduced PDI (PDI 1 mM GSH) was then perfused over the CT-coated sensor at either (A)
37 °C in pH 6.5 buffer or (B) 10 °C in pH 7.0 buffer. PDI was removed 400 s into the experiment and replacedwith sequential additions of anti-PDI, anti-CTA, and
anti-KDEL antibodies as indicated by the arrowheads. In panel A, an anti-CTB antibody was also perfused over the slide as indicated by the final arrowhead.
FIGURE 5. Association of PDI with CTA1 after holotoxin disassembly. CT
was appended to a SPR sensor slide coated with a polyclonal anti-CTA anti-
body, and a baseline measurement corresponding to the mass of the bound
holotoxin was recorded. Reduced PDI (PDI 1 mM GSH) was then perfused
over the CT-coated sensor at 37 °C. PDI was removed from the perfusion
buffer 400 s into the experiment and replacedwith sequential additions of an
anti-PDI antibody, an anti-CTB antibody, an anti-KDEL antibody, and an anti-
CTAmonoclonal antibody as indicated by the arrowheads. An identical result
was obtained when CT was initially appended to a sensor slide coated with
themonoclonal anti-CTA antibody and later detectedwith the anti-CTApoly-
clonal antibody.
FIGURE 6. Effect of PDI binding on CTA1 structure. FTIR spectra were
recorded for PDI (dashed line), 13C-labeled CTA1 (dotted line), or a 1:1 molar
ratio of PDI 13C-labeled CTA1 (solid line). All measurements were taken at
10 °C with 1 mM GSH in the pH 7.0 buffer.
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ordered conformation of CTA1 at 37 °C (17, 26, 27). Our FTIR
data thus demonstrated that physiological temperature alone
has a dramatic disordering effect on CTA1 structure, while the
interaction with PDI exerts little effect on the conformation of
CTA1.
To determine if the putative unfoldase activity of PDI could
be detected at temperatures greater than 10 °C, we performed
additional experiments in which reduced PDI was added to
CTA1 at 30 °C (supplemental Fig. S8) or to an acid-stabilized
CTA1 subunit at 37 °C (supplemental Fig. S9). Although a tem-
perature of 30 °C does not promote an optimal interaction
between PDI and CTA1 (Fig. 2), we chose this temperature
becausemost of the CTA1 protease sensitivity assays have been
performed at 30 °C (9, 13, 23, 29). PDI and CTA1 do not nor-
TABLE 1
PDI does not induce unfolding of the CTA1 polypeptide
Deconvolution of the conformation-sensitive amide I bands from FTIR data
presented in Figs. 7, S7, S8, and S9 was used to calculate, as detailed in supple-
mental data, the percentages of CTA1 structure under various conditions. The
means  standard deviations from four separate curve-fitting iterations are
shown.
% of CTA1 structure
Condition -Helix -Sheet Irregular Other
10 °C 37 1 45 3 8 2 9 2
10 °C PDI 36 1 44 2 8 1 10 2
30 °C 34 4 35 2 29 4 12 2
30 °C PDI 27 2 38 3 25 2 10 1
37 °C pH 6.5 29 2 37 4 25 3 9 2
37 °C pH 6.5 PDI 24 2 35 3 30 1 11 4
37 °C 21 2 15 4 53 2 11 4
FIGURE 7. Structure of CTA1 in the absence or presence of PDI as evaluated by FTIR at 10 °C. Curve-fitting (A and C) and second derivatives (B and D) for
the FTIR spectrum of 13C-labeled CTA1 recorded in the absence (A and B) or presence (C and D) of PDI are shown. In panels A and C, the dotted line represents
the sumofall deconvolutedcomponents (solid lines) fromthemeasured spectrum(dashed line). Note thatdifferentwavenumber scales areused inpanelsAand
B than in panels and C and D.
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mally interact at 37 °C (Fig. 2), so we used acidifiedmedium as a
means to facilitate PDI-CTA1 interactions at physiological
temperature (Fig. 3A). Previous CD analysis has shown that
CTA1 undergoes a progressive thermal disordering which is
inhibited by mildly acidic pH (27). The FTIR data were consis-
tent with this observation: the conformations of CTA1 at 30 °C
and 37 °C at pH 6.5 contained less secondary structure than the
10 °C toxin but more secondary structure than the toxin incu-
bated at 37 °C pH 7.0 (Table 1). At both 30 °C in neutral buffer
and 37 °C in acidified buffer, the FTIR data demonstrated that
reduced PDI does not substantially increase the percentage of
irregular structure in CTA1 (Table 1). Thus, the earlier data
that led to the unfoldase hypothesismay be interpreted in terms
of a PDI-induced effect onCTA1 at 30 °C that yields an ordered
but trypsin-sensitive toxin conformation. The ability of PDI to
displace CTA1 from the CT holotoxin at 30 °C in neutral buffer
(9) and at 37 °C in pH6.5 buffer (Fig. 4A) again indicated that an
unfoldase activity is not required for PDI to removeCTA1 from
CTA2/CTB5.
PDI Is Required for CT Intoxication But Not for CTA1
Translocation—To examine the in vivo interaction between
PDI and CT, we performed a CT toxicity assay in the TZM 1–2
cell line that is stably transfected with a PDI siRNA (42, 43).
Experiments were also conducted with the parental TZM cells
and with a TZM 5-1 cell line stably transfected with a nonspe-
cific control siRNA (Fig. 8A). As expected, TZM 1-2 cells were
completely resistant to CT. TZM 5-1 cells transfected with the
control siRNAonly exhibited aminor degree of toxin resistance
at the highest CT concentration, thus confirming that CT
resistance in the TZM 1-2 cell line was specifically due to the
loss of PDI expression. PDI was therefore essential for holo-
toxin disassembly and productive CT intoxication.
Our collective data suggested that PDI is only needed to dis-
place CTA1 from CTA2/CTB5; the dissociated CTA1 subunit
can then unfold spontaneously to trigger its ERAD-mediated
dislocation. To test this model, we performed a transfection-
based CTA1 toxicity assay in the TZM, TZM 1–2, and TZM
5–1 cell lines (Fig. 8B). A plasmid-based system was used to
express CTA1 directly in the ER of transfected cells (35). cAMP
levels were then quantified at 3 h post-transfection. To control
for possible differences in transfection efficiencies between the
cell lines, CTA1 was radiolabeled and immunoprecipitated
from parallel sets of transfected cells. Results from the cAMP
assay were subsequently standardized to CTA1 expression lev-
els. AlthoughTZM1–2 cells were completely resistant to exog-
enously applied CT holotoxin, they exhibited no resistance to
the ER-localized CTA1 construct. In fact, the cAMP levels in
TZM 1-2 cells expressing ER-localized CTA1 were slightly ele-
vated in comparison to the cAMP levels generated from CTA1
expression in either the parental TZMcells or TZM5-1 control
cells. Collectively, this data indicated that PDI function is not
required for ER-localized CTA1 to enter the cytosol.
Previous work with metabolically labeled cells has demon-
strated that the entire detectable pool of plasmid-expressed
CTA1 is inserted into the ER (44). Yet, if the co-translational
targeting of our ER-localized CTA1 construct was not com-
pletely efficient, then the CTA1 toxicity assay would be com-
promised by the small fraction of CTA1 that was synthesized in
the cytosol rather than in the ER. To control for this possibility,
we directlymonitored the ER-to-cytosol translocation of trans-
fected CTA1 in the parental TZM, TZM 1-2, and TZM 5-1 cell
lines. Transfected, radiolabeled cells were partitioned into sep-
arate membrane and cytosolic fractions according to estab-
lished protocols (26, 29, 34, 45). Material immunoprecipitated
from each fraction with an anti-CTA antibody was then
resolved by SDS-PAGE and quantified using PhosphorImager
analysis. As shown in Fig. 8C, approximately equivalent
amounts of CTA1 were recovered from the cytosolic fractions
of all three cell lines. Thus, the lack of PDI in TZM 1-2 cells did
not inhibit the ER-to-cytosol export of transfected CTA1. The
results of Fig. 8 demonstrated that PDI is required for produc-
tive intoxicationwith exogenously appliedCTbut is not needed
FIGURE 8. In vivo role of PDI in CT intoxication and CTA1 translocation. A, parental TZM cells, TZM 1-2 cells stably transfected with PDI siRNA, and TZM 5-1
cells stably transfected with a nonspecific control siRNA were exposed to the stated concentrations of CT for 2 h. Toxicity was then assessed from the rise in
intracellular cAMP. The averages standard deviations of three independent experiments with triplicate samples are shown. B, TZM, TZM 1-2, and TZM 5-1
cells were transfected with a plasmid encoding a CTA1 subunit appendedwith an ER-targeting sequence. cAMP levels recorded at 3 h post-transfection were
standardized to CTA1 expression levels, and the resulting data were plotted as percentages of the control response from parental TZM cells. The averages
ranges of two independent experiments are shown. C, TZM, TZM 1-2, and TZM 5-1 cells were transfected with a plasmid encoding a CTA1 subunit appended
with an ER-targeting sequence. CTA1 immunoprecipitated from themembrane (P, pellet) and cytosolic (S, supernatant) fractions ofmetabolically labeled cells
were resolved by SDS-PAGE. The averages ranges of cytosolic CTA1 calculated from two independent experiments are shown in the graph.
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for translocation of the isolated CTA1 subunit. As such, it
appears that the only role of PDI in cholera intoxication is to
displace CTA1 from the CT holotoxin.
DISCUSSION
For CTA1 translocation, PDI has been proposed to act as a
redox-dependent chaperone that actively unfolds the holo-
toxin-associated CTA1 subunit to separate CTA1 from the rest
of the toxin (9). The unfoldase activity of PDI in this process is,
to the best of our knowledge, a unique property that has not
been reported for PDI interactions with any other substrate.
Furthermore, the proposed unfoldase activity of PDI is based
upon a protease sensitivity assay that only serves as an indirect
measure of protein folding (9, 13, 23, 28, 29). In this work, we
demonstrated that PDI is required for disassembly of the CT
holotoxin but does not unfold theCTA1 subunit. CTA1unfolds
spontaneously after its dissociation from CTA2/CTB5 at phys-
iological temperature (17, 26). PDI-mediated disassembly of
the CT holotoxin thus leads to the spontaneous unfolding of
dissociated CTA1, but PDI itself does not function as an unfol-
dase to actively unfold CTA1.
Using SPR, we were able tomonitor the PDI-mediated disas-
sembly of the CT holotoxin in real time. The kinetics of holo-
toxin disassembly were linked to the available concentration of
PDI (supplemental Fig. S2). Holotoxin disassembly required
the reduced form of PDI and did not occur in the presence of
reducing agent alone (Fig. 1). These results were consistent
with previous reports (9, 36), as was the observed retention of
CTA2withCTB5 after release of CTA1 from the holotoxin (Fig.
1B) (46). We could thus faithfully reconstitute the process of
CT disassembly on an SPR sensor slide.
Conditions that block CTA1 unfolding in vitro also block the
ER-to-cytosol export of CTA1 in vivo (26, 27). However, con-
ditions that block CTA1 unfolding do not block CTA1 dissoci-
ation from the CT holotoxin: reduced PDI could separate
CTA1 from CTA2/CTB5 in the presence of acidic pH (Fig. 4A)
or 10% glycerol (26). Secretion of the free A1 subunit from
glycerol-treated cells (26) further suggested that in vivo unfold-
ing of CTA1 is unnecessary for toxin disassembly: only folded
proteins exit the ER for secretory transport, so the secreted pool
of CTA1 must have been in a folded conformation. CT disas-
sembly could also occur at 4 °C (supplemental Fig. S4), a tem-
perature that maintains CTA1 in a folded conformation and
prevents the PDI-induced shift of CTA1 to a protease-resistant
conformation (29). Collectively, these results strongly sug-
gested that CTA1 unfolding is not required for CTA1 dissoci-
ation from the rest of the toxin. In further support of this inter-
pretation, we demonstrated that the thermal denaturation of
reduced but holotoxin-associatedCTA1did not displaceCTA1
from its non-covalent assembly in the CT holotoxin (supple-
mental Fig. S5). A similar observation was previously made by
Goins and Friere with the technique of differential scanning
calorimetry (37). Thus, PDI apparently removes CTA1 from
CTA2/CTB5 by amechanism that does not involve unfolding of
the holotoxin-associated CTA1 subunit.
To directly examine the putative unfoldase activity of PDI,
we employed the structural technique of isotope-edited FTIR
spectroscopy. Experiments were performed under three condi-
tions that facilitate PDI-CTA1 interactions and support PDI-
mediated disassembly of the CT holotoxin: 10 °C, 30 °C, and
37 °C at pH 6.5. For each condition, deconvolution of the con-
formation-sensitive amide I bands demonstrated that PDI did
not substantially alter the percentage of irregular structure in
CTA1 and, thus, did not unfold the CTA1 polypeptide (Table
1). In contrast, heating CTA1 alone at neutral pH shifted the
percentage of its irregular structure from 8% at 10 °C to 53% at
37 °C at the expense of both -helix and -sheet structures
(Table 1). CT disassembly therefore occurs under conditions
that do not involve substantial PDI-induced disordering of the
CTA1 polypeptide. These results, which represent the first
direct examination of the impact of PDI binding on CTA1
structure, demonstrated that CTA1 is unfolded by physiologi-
cal temperature (due to its intrinsic thermal instability) but not
by PDI.
The unfoldase activity of PDI has only been described with a
biochemical protease sensitivity assay. Using this method, the
folding state of a protein is inferred from its susceptibility to
proteolysis: a folded protein is generally more resistant to pro-
teolysis than an unfolded variant of the same protein. The
resistance of CTA1 to trypsin-mediated proteolysis, combined
with the sensitivity of PDI-treated CTA1 to proteolysis, thus
yielded the conclusion that PDI actively unfolds the CTA1 sub-
unit. Unfortunately, interpretation of these experiments is
complicated by the conformational shift in CTA1 that occurs
upon its separation from the holotoxin and by the unstable,
heat-labile nature of the free A1 subunit (17). Protease concen-
tration can also affect the outcome of the experiment, as can the
temperature of the experiment (17, 26, 28). It should be noted
that most experiments to monitor the “unfoldase” activity of
PDI have been performed at 30 °C (9, 13, 23, 29), but incubation
of CTA1 alone at 37 °C will induce the toxin to assume a pro-
tease-sensitive conformation (17, 26) (supplemental Fig. S10).
Furthermore, the sensitivity of PDI-treated CTA1 to proteoly-
sis depends upon the protease used: the toxin is more sensitive
to trypsin (9) than to the thermolysin protease which cleaves
bulky and aromatic residues (supplemental Fig. S10). These
issues suggest that protease sensitivity is a poor, indirect mea-
sure of the purported conformational change required for
CTA1 dissociation from the CT holotoxin. More important,
however, is the disconnect between the PDI-induced shift of
CTA1 to a trypsin-sensitive conformation and the PDI-medi-
ated disassembly of the CT holotoxin. PDI does not induce
CTA1 to assume a protease-sensitive conformation at 4 °C (29),
yet PDI can still displace CTA1 from CTA2/CTB5 at 4 °C (sup-
plemental Fig. S4). These results demonstrate that the PDI-
induced shift of CTA1 to a protease-sensitive conformation,
which has been interpreted as an unfolding event (9, 13, 23, 28,
29), does not correlate to the PDI-induced separation of CTA1
from CTA2/CTB5.
PDI binds to folded but not unfolded conformations ofCTA1
(Figs. 1–3). The spontaneous unfolding of CTA1 that occurs
upon holotoxin disassembly at 37 °C thus displaces the toxin-
bound PDI (Figs. 3 and 5). This observation is consistent with a
previous report that concluded PDI-substrate interactions can
be disrupted by changes to the structure of the substrate (24).
However, our results conflict with the model of CTA1-PDI
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interactions that proposes PDI oxidation by Ero1p is responsi-
ble for displacing toxin-bound PDI (23). That model is based
upon studies performed at temperatures below 37 °C. While
Ero1p clearly regulates the redox status of PDI (22, 23, 47, 48),
our results strongly suggest that Ero1p function is not required
to release PDI from CTA1 at physiological temperature.
As demonstrated with cell-based assays, CTA1 translocation
does not require PDI function after disassembly of the holo-
toxin. PDI-deficient cell lines were completely resistant to
exogenously applied CT, as expected from its essential role in
separating CTA1 from CTA2/CTB5. However, the same PDI-
deficient cells displayed wild-type sensitivity to a CTA1 con-
struct that was directly expressed in the ER of transfected cells.
This experimental condition, whichmimicked the status of ER-
localized CTA1 after its dissociation from the holotoxin, dem-
onstrated that PDI is not required for the ER-to-cytosol export
of free CTA1. Direct monitoring of the CTA1 translocation
event provided further support for this conclusion.
Based on the available biophysical, biochemical, and cell
biological data, we propose the following revised model of
CTA1 translocation. CT travels from the cell surface to the
ER as an intact holotoxin (4). The disulfide bond linking
CTA1 to CTA2/CTB5 is reduced at the resident redox state
of the ER (8). However, at this point CTA1 remains anchored
to the holotoxin through non-covalent interactions (9, 36).
Reduced PDI then binds to a region in the A11 subdomain of
CTA1 and physically displaces CTA1 from the holotoxin.
Released from the structural constraints of its non-covalent
interactions with CTA2/CTB5, the dissociated CTA1 sub-
unit undergoes a thermal transition to a partially unfolded
conformation (17). This unfolding event, which occurs
spontaneously at 37 °C, displaces the toxin-bound PDI and
identifies free CTA1 as a misfolded protein for processing by
the ERAD system. CTA1 is consequently delivered to the
Sec61p and/or Derlin-1 pores for Hsp90-mediated extrac-
tion to the cytosol (21, 25, 34, 49, 50). An interaction with
ARF and possibly other host factors then allows the cytosolic
pool of CTA1 to regain an active conformation for the ADP-
ribosylation of its Gs target (16–18).
Toxin-ERAD interactions involving pertussis toxin (PT) and
ricin may follow a similar pattern to CT. Like CTA1, the cata-
lytic PTS1 subunit shifts to a disordered conformation after
separation from its B oligomer at physiological temperature
(51). This conformational shift would identify PTS1 as an
ERAD substrate and thereby facilitate PTS1 passage into the
cytosol. Ricin A chain is more stable than either CTA1 or PTS1
(52), but an interaction with anionic phospholipids of the ER
membrane at 37 °C induces ricin A chain to assume a disor-
dered conformation that would be treated as an ERAD sub-
strate (53, 54). Furthermore, the interaction between PDI and
ricin mirrors the interaction between PDI and CT: PDI is
responsible for disassembly of the ricin holotoxin but does not
unfold ricin A chain (55, 56). Our results are thus consistent
with a general model of toxin translocation in which PDI-me-
diated toxin disassembly and temperature-induced A chain
unfolding are used in similar fashion by multiple ERAD-ex-
ploiting toxins.
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